Latest revision as of 11:59, 6 July 2024

Back to Top

Section editor
	Marjorie G. Zauderer, MD, MS, FACP Memorial Sloan Kettering Cancer Center New York, NY, USA

1 regimens on this page 1 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

EURACAN/PSOGI

2020: Kusamura et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up PubMed

NCCN

NCCN Guidelines - Mesothelioma: Peritoneal
- 2023: Ettinger et al. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. PubMed

Advanced or metastatic disease, subsequent lines of therapy

Atezolizumab & Bevacizumab

Regimen

Study	Dates of enrollment	Evidence
Raghav et al. 2021 (MDACC 2016-0861)	2017-2019	Phase 2

Immunotherapy

Atezolizumab (Tecentriq) 1200 mg IV once on day 1

Targeted therapy

Bevacizumab (Avastin) 15 mg/kg IV once on day 1

21-day cycles

References

MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article contains dosing details in manuscript PubMed NCT03074513

@@ Line 1: / Line 1: @@
-{{#lst:Section editor transclusions|gi}}
+<span id="BackToTop"></span>
+<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
+[[#top|Back to Top]]
+</div>
+{{#lst:Editorial board transclusions|meso}}
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 5: / Line 9: @@
 <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 |}
 {{TOC limit|limit=3}}
 =Guidelines=
+'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 ==EURACAN/PSOGI==
-*'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up]
+*'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/32209311 PubMed]
-==[https://www.nccn.org/ NCCN]==
+==NCCN==
-*[https://www.nccn.org/professionals/physician_gls/pdf/mpem.pdf NCCN Guidelines - Malignant Peritoneal Mesothelioma]
+*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1513 NCCN Guidelines - Mesothelioma: Peritoneal]
+**'''2023:''' Ettinger et al. [https://doi.org/10.6004/Jnccn.2023.0045 Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.] [https://pubmed.ncbi.nlm.nih.gov/37673108/ PubMed]
 =Advanced or metastatic disease, subsequent lines of therapy=
 ==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
+<div class="toccolours" style="background-color:#eeeeee">
-|-
-|[[#top|back to top]]
-|}
 ===Regimen {{#subobject:6d0c87|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
 !style="width: 33%"|Study
-!style="width: 33%"|Years of enrollment
+!style="width: 33%"|Dates of enrollment
 !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
-|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ Raghav et al. 2021 (MDACC 2016-0861)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ Raghav et al. 2021 (MDACC 2016-0861)]
 |2017-2019
 | style="background-color:#91cf61" |Phase 2
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Immunotherapy====
 *[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1
 ====Targeted therapy====
 *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
 '''21-day cycles'''
+</div></div>
 ===References===
-#'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/34261675/ PubMed] NCT03074513
+#'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34261675/ PubMed] [https://clinicaltrials.gov/study/NCT03074513 NCT03074513]
 [[Category:Malignant peritoneal mesothelioma regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Gastrointestinal cancers]]
-[[Category:Mesothelioma]]
+[[Category:Mesotheliomas]]

Difference between revisions of "Malignant peritoneal mesothelioma"